Discontinued — last reported Q4 '25
Year-over-year, this metric grew by 151.9%, from $265.30M to $668.20M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows relatively stable performance with a 0.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $5.20M | $251.20M | $110.00M | -$400.00K | $0.00 | $118.50M | $215.70M | $215.70M | $215.70M | $215.70M | $0.00 | $5.20M | $174.50M | $600.00K | $265.30M | $10.20M | $500.00K | $0.00 | $668.20M |
| QoQ Change | — | — | >999% | -56.2% | -100.4% | +100.0% | — | +82.0% | +0.0% | +0.0% | +0.0% | -100.0% | — | >999% | -99.7% | >999% | -96.2% | -95.1% | -100.0% | — |
| YoY Change | — | — | — | — | — | -100.0% | -52.8% | +96.1% | >999% | — | +82.0% | -100.0% | -97.6% | -19.1% | -99.7% | — | +96.2% | -99.7% | -100.0% | +151.9% |